

## LETTERS

# Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Shideng Bao<sup>1,2</sup>, Qiulian Wu<sup>1,2</sup>, Roger E. McLendon<sup>2,3</sup>, Yueling Hao<sup>1,2</sup>, Qing Shi<sup>1,2</sup>, Anita B. Hjelmeland<sup>1,2</sup>, Mark W. Dewhurst<sup>4</sup>, Darell D. Bigner<sup>2,3</sup> & Jeremy N. Rich<sup>1,2,5,6</sup>

**Ionizing radiation represents the most effective therapy for glioblastoma (World Health Organization grade IV glioma), one of the most lethal human malignancies<sup>1</sup>, but radiotherapy remains only palliative<sup>2</sup> because of radioresistance. The mechanisms underlying tumour radioresistance have remained elusive. Here we show that cancer stem cells contribute to glioma radioresistance through preferential activation of the DNA damage checkpoint response and an increase in DNA repair capacity. The fraction of tumour cells expressing CD133 (Prominin-1), a marker for both neural stem cells and brain cancer stem cells<sup>3–6</sup>, is enriched after radiation in gliomas. In both cell culture and the brains of immunocompromised mice, CD133-expressing glioma cells survive ionizing radiation in increased proportions relative to most tumour cells, which lack CD133. CD133-expressing tumour cells isolated from both human glioma xenografts and primary patient glioblastoma specimens preferentially activate the DNA damage checkpoint in response to radiation, and repair radiation-induced DNA damage more effectively than CD133-negative tumour cells. In addition, the radioresistance of CD133-positive glioma stem cells can be reversed with a specific inhibitor of the Chk1 and Chk2 checkpoint kinases. Our results suggest that CD133-positive tumour cells represent the cellular population that confers glioma radioresistance and could be the source of tumour recurrence after radiation. Targeting DNA damage checkpoint response in cancer stem cells may overcome this radioresistance and provide a therapeutic model for malignant brain cancers.**

Glioblastomas are the most lethal primary brain tumour with a median survival of less than 12 months because of resistance to radiation and other treatments<sup>1</sup>. Glioblastomas present as diffuse tumours with invasion into normal brain, but frequently recur or progress after radiation as focal masses<sup>2</sup>, suggesting that only a fraction of tumour cells is responsible for regrowth. Identification of a crucial cellular subpopulation of brain tumour cells with potent tumorigenic activity<sup>3–5,7</sup> supports the cancer stem cell hypothesis in solid tumours. As glioma subpopulations expressing Prominin-1 (CD133<sup>+</sup>) are enriched for cancer stem cells and show greater tumorigenic potential than do CD133<sup>-</sup> cells<sup>3–5</sup>, we have examined the role of glioma cancer stem cells in the development of radioresistance.

We found that ionizing radiation (IR) treatment of short-term cultures from human glioma xenografts enriched the CD133<sup>+</sup> subpopulation fourfold relative to untreated cultures (Fig. 1a, b). Likewise, glioma xenografts irradiated *in vivo* were enriched 3–5-fold for CD133<sup>+</sup> cells relative to untreated xenografts (Fig. 1c). Similar results were seen in freshly isolated glioblastoma tumour specimens: the basal fraction of CD133<sup>+</sup> cells was 2–3% and increased to 6–10% after IR treatment (Fig. 1d). Irradiation did not induce CD133

expression in CD133<sup>-</sup> tumour cells (Supplementary Fig. S1), confirming that increased CD133<sup>+</sup> fractions after IR were caused by enrichment of original CD133<sup>+</sup> subpopulations. In addition, two radioresistant human glioma cell subpopulations derived from short-term cultures of glioma xenografts subjected to three serial cycles of IR also contained greater percentages of CD133<sup>+</sup> cells than parental populations (Supplementary Fig. S2). Thus, tumours surviving IR are enriched in CD133<sup>+</sup> cancer cells.

To define the biological significance of CD133<sup>+</sup> enrichment after IR, we implanted a constant number of tumour cells with increasing percentages of CD133<sup>+</sup> cells into the frontal lobes of immunocompromised mice. Increased CD133<sup>+</sup> cell fractions dose-dependently decreased tumour latency and enhanced tumour growth and vascularity (Fig. 1e, f, and data not shown). Consistent with these results, viable tumour cells from irradiated xenografts were enriched for CD133<sup>+</sup> cells and formed secondary tumours with decreased latencies relative to untreated xenografts (Supplementary Fig. S3). Thus, enrichment of CD133<sup>+</sup> cells is crucial in glioma recurrence after radiotherapy.

To confirm that purified CD133<sup>+</sup> subpopulations are enriched for cancer stem cells, we characterized CD133<sup>+</sup> and CD133<sup>-</sup> cells derived from glioma xenografts and primary human glioblastoma samples. Murine host contamination of CD133<sup>-</sup> cellular subpopulations from xenografts was ruled out with the pan-human antibody 3B4, which binds to a glycoprotein only on human cells<sup>8</sup> (Supplementary Fig. S4). The neoplastic origin of cells derived from the human biopsy specimens was confirmed through fluorescent *in situ* hybridization (FISH) analysis of genetic markers altered in the original patient tumour specimen (Supplementary Fig. S5 and data not shown). CD133<sup>+</sup> tumour cells showed characteristics consistent with cancer stem cells<sup>3–7,9–11</sup>: namely, neurosphere formation (Fig. 2a); expression of neural and/or cancer stem cell markers, including CD133, Sox2, Musashi and Nestin (Fig. 2b); and multilineage differentiation with markers for astrocytes (GFAP, S100 $\beta$ ), neurons (Map-2, TUJ1) or oligodendrocytes (O4, GalC) (Supplementary Figs S6 and S7a). CD133<sup>+</sup> cells derived from xenografts or biopsy specimens formed neurospheres (76–89%; Supplementary Table 1), whereas CD133<sup>-</sup> cells rarely formed neurospheres. CD133<sup>+</sup> tumour cells were highly tumorigenic in brains of immunocompromised mice with characteristics of glioblastomas (Fig. 2c–e and Supplementary Table 1) in concordance with previous reports<sup>3–5</sup>. CD133<sup>-</sup> cells did not form detectable tumours even when implanted at  $2 \times 10^6$  cells per mouse, except for occasional tumours from a single xenograft source (D456MG paediatric xenografts; Fig. 2c and Supplementary Table 1). Of note, we used a shorter incubation period in our mouse studies than some other researchers<sup>3,7</sup>. Longer incubation periods may permit greater regrowth of poorly

<sup>1</sup>Department of Surgery, <sup>2</sup>Preston Robert Tisch Brain Tumor Center, <sup>3</sup>Department of Pathology, <sup>4</sup>Department of Radiation Oncology, <sup>5</sup>Department of Medicine, and <sup>6</sup>Department of Neurobiology, Duke University Medical Center, Durham, North Carolina 27710, USA.


tumorigenic cells but increases the probability of secondary genetic changes. Thus, CD133<sup>+</sup> subpopulations derived from patient glioma specimens and xenografts are enriched for characteristics of cancer stem cells, including tumorigenesis *in vivo*.

To identify further the cell subpopulations that contribute to glioma radioresistance, we studied the radiosensitivity of CD133<sup>+</sup> and CD133<sup>-</sup> tumour cell subpopulations. Colony formation assays confirmed that CD133<sup>+</sup> cells isolated from xenografts and a biopsy specimen were more resistant to IR treatment than were corresponding CD133<sup>-</sup> cells (Fig. 3a and Supplementary Fig. S8a). The differential radioresistance between the two subpopulations was consistent regardless of the presence of growth factors (Supplementary Figs S9 and S10). The preferential survival of CD133<sup>+</sup> cells after irradiation was due to lower rates of apoptosis, as indicated by decreased activation of caspase-3 in CD133<sup>+</sup> cells from irradiated cultures or xenografts (Fig. 3b and Supplementary Fig. S8b). In addition, annexin V


staining showed that IR-induced apoptosis in CD133<sup>+</sup> cells was 4–5-fold lower than that in matched CD133<sup>-</sup> cells isolated from primary glioblastomas (Supplementary Fig. S11).

To verify the preferential survival of CD133<sup>+</sup> cells after IR, matched CD133<sup>+</sup> and CD133<sup>-</sup> cells from a xenograft or patient biopsy specimen were differentially labelled with fluorescent dyes<sup>12,13</sup> and mixed in defined ratios. In the absence of IR, the relative percentage of cells derived from CD133<sup>+</sup> cells increased only modestly over time. By contrast, the percentage of CD133<sup>+</sup>-derived cells after irradiation increased more than fourfold (Fig. 3c, d, and Supplementary Fig. S12), confirming that CD133<sup>+</sup> tumour cells have greater radioresistance and repopulation potential than do CD133<sup>-</sup> cells *in vitro*.

We examined the capacity of CD133<sup>+</sup> glioma cells to form tumours after irradiation in several assays. In an *in vivo* limiting dilution tumour formation assay, irradiated CD133<sup>+</sup> cells from a




**Figure 1 | Enrichment of CD133<sup>+</sup> tumour subpopulations after irradiation *in vitro* and *in vivo*, and enhancement of intracranial tumour formation by increased CD133<sup>+</sup> fraction.** **a**, Glioma cultures from D54MG xenografts were untreated or irradiated (5 Gy). CD133<sup>+</sup> fractions were assayed by FACS after 48 h. **b**, Mean  $\pm$  s.d. results from **a** ( $n = 3$ ;  $*P < 0.001$ ). **c**, Subcutaneous (SC) and intracranial (IC) D456MG xenografts were irradiated ( $3 \times 5$  Gy or  $1 \times 9$  Gy) or untreated. CD133<sup>+</sup> fractions were quantified after 48 h (mean  $\pm$  s.d.,  $n = 3$ ;  $*P < 0.002$ ;  $**P < 0.001$ ). **d**, Individual patient tumour specimens were halved and either irradiated with 2 Gy or untreated. The CD133<sup>+</sup> fraction in each sample was quantified by FACS. **e**, **f**, CD133<sup>+</sup> and CD133<sup>-</sup> cells from glioblastoma specimen T3359 were mixed in different ratios and xenotransplanted into mouse brains (100,000 total cells per mouse). **e**, Survival until development of neurological signs (mean  $\pm$  s.d.,  $n = 5$ ;  $*P < 0.002$ ;  $**P < 0.001$ ). **f**, Representative images of brains bearing secondary tumours.



**Figure 2 | Characterization of CD133<sup>+</sup> and CD133<sup>-</sup> cells from human glioma xenografts and primary glioblastoma specimens.** **a**, Representative images of neurospheres from CD133<sup>+</sup> cells from D456MG xenografts and glioblastoma specimens (T3379, T3317). **b**, Neurospheres from **a** expressed neural stem cell markers (CD133, Nestin, Sox2 and Musashi), as assessed by immunofluorescence. **c**, Untreated or irradiated (3 Gy) CD133<sup>+</sup> cells ( $10^4$ ) from glioblastoma specimen T3359 and from D456MG xenografts were transplanted into brains of immunocompromised mice ( $n = 5$ ). Mice were killed on development of neurological signs or after 8 weeks. CD133<sup>+</sup> cells formed haemorrhagic masses regardless of irradiation. T3359 CD133<sup>-</sup> cells did not generate tumours. D456MG CD133<sup>-</sup> cells ( $2 \times 10^6$ ) formed small tumours in two out of five brains. **d**, Representative photomicrographs of tumours from **c** (stained with haematoxylin and eosin). **e**, Immunofluorescent staining of frozen sections of the tumours generated by untreated and irradiated CD133<sup>+</sup> cells in **c**. Cells were stained for the GFAP astrocyte marker (green) and the O4 oligodendrocyte marker (red).


xenograft or patient specimen treated with a clinically relevant IR dose (2 Gy) formed tumours with similar potency to untreated CD133<sup>+</sup> cancer cells, although treatment of CD133<sup>+</sup> cells with 5 Gy of IR reduced tumorigenicity (Supplementary Table 2). 2-Gy-irradiated CD133<sup>+</sup> tumour cells derived from human glioblastoma biopsy specimens or xenografts formed tumours with similar latencies to non-irradiated CD133<sup>+</sup> tumour cells (Fig. 2c–e and Supplementary Fig. S13a). In addition, irradiated CD133<sup>+</sup> cells retained multilineage differentiation potential (Supplementary Fig. S7b) and formed tumours with heterogeneous tumour cell populations expressing markers of different lineages *in vivo* (Fig. 2d, e). Viable CD133<sup>+</sup> cells from *in vivo* irradiated xenografts or patient specimens transiently grown in mice formed secondary tumours with similar latencies to CD133<sup>+</sup> tumour cells from matched non-irradiated control tumours (Supplementary Fig. S13b). By contrast, the same dose of irradiation abolished the tumorigenic capacity of



**Figure 3 | CD133<sup>+</sup> tumour cells show radioresistance and lower sensitivity to radiation-induced apoptosis than CD133<sup>-</sup> tumour cells dependent on checkpoint kinase activity.** **a**, CD133<sup>+</sup> and CD133<sup>-</sup> tumour cells were untreated or treated with 5 Gy of IR, a Chk1/Chk2 low molecular weight inhibitor (debromohymenialdisine, DBH, 3 μM), or a combination of both. Representative images of colony formation are shown. **b**, CD133<sup>+</sup> and CD133<sup>-</sup> cells derived from primary glioblastoma T3590 or D456MG xenografts were untreated or irradiated with 2 Gy or 5 Gy of IR. Whole-cell lysates were collected after 24 h and immunoblotted for cleaved caspase-3, an indicator of cell apoptosis. **c**, CD133<sup>+</sup> and CD133<sup>-</sup> cells derived from primary glioblastoma T3590 were labelled separately with CFSE (green) and CMTRX (red) fluorescent dyes, mixed in defined ratios (5% CD133<sup>+</sup>), and visualized by fluorescent microscopy at the indicated time points. **d**, Mean ± s.d. results from **c** ( $n = 100$  cells in three trials; \* $P < 0.002$ ; \*\* $P < 0.001$ ).

D456MG CD133<sup>-</sup> tumour cells that showed weak basal tumour formation (Supplementary Fig. S13c). Thus, CD133<sup>+</sup> glioma cell subpopulations are enriched with cancer stem cells resistant to radiation *in vitro* and *in vivo* in comparison to matched CD133<sup>-</sup> glioma cells.

Although IR damages tumour cells through several mechanisms, IR kills cancer cells primarily through DNA damage. Thus, DNA damage checkpoint responses play essential roles in cellular radiosensitivity<sup>14–20</sup>. To determine the role of DNA damage checkpoint responses in glioma cancer stem cell radioresistance, we compared early DNA damage checkpoint responses in CD133<sup>+</sup> and CD133<sup>-</sup> glioma tumour cell subpopulations. In both CD133<sup>+</sup> and CD133<sup>-</sup> cells derived from human glioma xenografts, DNA damage induced by IR or a radiomimetic, neocarzinostatin, potentially initiated activating phosphorylation of the ataxia-telangiectasia-mutated (ATM), Rad17, Chk1 and Chk2 checkpoint proteins (Fig. 4a and Supplementary Fig. S14a). However, activating phosphorylation of these checkpoint proteins was significantly higher in CD133<sup>+</sup> cells than in CD133<sup>-</sup> cells (Fig. 4a and Supplementary Fig. S14a), indicating that CD133<sup>+</sup> cells show greater checkpoint activation in response to DNA damage. Similarly, CD133<sup>+</sup> cells isolated from several human glioblastoma specimens showed a marked increase in activation of several checkpoint proteins in response to DNA damage relative to CD133<sup>-</sup> cells (Fig. 4b, c, and Supplementary Fig. S14b). Rad17, a



**Figure 4 | CD133<sup>+</sup> glioma cells preferentially activate the DNA damage checkpoint and repair IR-induced DNA damage more efficiently than CD133<sup>-</sup> cells.** **a–c**, The activation state of the checkpoint response in matched CD133<sup>+</sup> and CD133<sup>-</sup> cells from glioma D456MG xenografts (**a**) and glioblastoma specimens (**b**, **c**) was assessed before treatment (–) and 1 h after 3 Gy of IR (+). Whole-cell lysates were immunoblotted for phosphorylated and total amounts of checkpoint proteins (ATM, Rad17, Chk2 and Chk1). **d**, CD133<sup>+</sup> and CD133<sup>-</sup> cells derived from primary glioblastoma T3539 were irradiated with 3 Gy of IR. The presence of DNA damage at sequential time points after damage was assessed by single-cell gel electrophoresis assay under alkaline conditions (alkaline comet assay). **e**, Quantification of the percentages of cells with comet tails at different time points after IR in CD133<sup>+</sup> and CD133<sup>-</sup> populations. Data are the means ± s.d. ( $n = 100$  cells in three trials; \* $P < 0.001$ ; \*\* $P < 0.002$ ).

crucial regulator of the DNA damage checkpoint<sup>19</sup>, also showed significantly greater baseline phosphorylation of a key regulatory residue (Ser 645) in CD133<sup>+</sup> cells than in CD133<sup>-</sup> cells in most cases, suggesting that the CD133<sup>+</sup> subpopulation may be primed to respond to DNA damage. In addition, IR distinctly increased ATM kinase activity in the CD133<sup>+</sup> subpopulation derived from primary glioblastoma biopsy specimens in response to IR (Supplementary Fig. S14c). These data show that CD133<sup>+</sup> glioma cells can activate checkpoint responses to a greater extent than CD133<sup>-</sup> cells, suggesting that the resistance of CD133<sup>+</sup> cells to IR is due to preferential checkpoint activation.

The primary downstream effect of checkpoint activation is to induce cell-cycle arrest to repair damaged DNA. We compared the recovery of CD133<sup>+</sup> and CD133<sup>-</sup> cells derived from both xenografts and biopsy specimens in response to IR-induced DNA damage using the alkaline comet assay<sup>21</sup>. CD133<sup>+</sup> and CD133<sup>-</sup> cells from glioma xenografts or human patient biopsy specimens were equally susceptible to DNA damage to IR initially, but the percentage of cells with comet tails decreased 4–9 times more rapidly in CD133<sup>+</sup> cells than in matched CD133<sup>-</sup> cells (Fig. 4d, e, and Supplementary Fig. S15), indicating that CD133<sup>+</sup> cells repaired the DNA damage more efficiently than CD133<sup>-</sup> cells. This result was further confirmed by assessing the resolution of phosphorylated histone 2AX nuclear foci<sup>22</sup> after IR (Supplementary Fig. S16). The ability to repair DNA damage is essential to cellular survival because maintained DNA breaks induce apoptosis or senescence<sup>14–16</sup>. Thus, the CD133<sup>+</sup> tumour cells would be expected preferentially to survive radiation to repopulate the tumour.

To determine the contribution of the preferential activation of DNA damage checkpoint to the increased survival of CD133<sup>+</sup> cells after IR administration, we assessed the ability of an inhibitor, debromohymenialdisine (DBH), of checkpoint kinases Chk1 and Chk2 (ref. 23) to prevent CD133<sup>+</sup> cell resistance to IR. Pretreatment with DBH minimally impacted the proliferation of both CD133<sup>+</sup> and CD133<sup>-</sup> cells, but DBH treatment showed synergy with IR to disrupt the radioresistance of CD133<sup>+</sup> cells *in vitro* (Fig. 3a). Similar results were obtained in *in vivo* mouse studies (Supplementary Fig. S17). These data confirm that preferential checkpoint response in CD133<sup>+</sup> cancer cells is closely associated with the cellular resistance to radiation.

Together, our results show that CD133<sup>+</sup> cancer cells contribute to glioma radioresistance and tumour repopulation through preferential checkpoint response and DNA repair, and targeting of checkpoint response in CD133<sup>+</sup> cancer cells can overcome glioma radioresistance *in vitro* and *in vivo*, which may provide a therapeutic advantage to reduce brain tumour recurrence. The specific molecular mechanism for the resistance of cancer stem cells to IR can be linked to the function of the DNA damage checkpoint. As the cell cycle of a normal stem cell is tightly controlled by the checkpoint to maintain genomic stability and integrity, the defective checkpoint responses associated with early cancer development<sup>24,25</sup> implicate abnormal checkpoint control as a potential contributor to the transformation of normal cells into cancer stem cells. Future studies may define similar contributions of the cancer stem cell to therapeutic responses in other solid cancers with similar molecular mechanisms. Therapies targeted to the checkpoint kinases in preclinical and clinical development may provide a specific method to disrupt this resistance mechanism to improve overall tumour control with radiation treatment.

## METHODS

Additional and more detailed methods are presented in the Supplementary information.

**Human glioma xenografts and glioblastoma specimens.** D54MG xenografts were derived from A172. D456MG xenografts were derived from a paediatric glioblastoma biopsy directly implanted into immunocompromised mice. Primary glioblastoma samples (designated T3xxx) were obtained from patients

undergoing resection in accordance with a protocol approved by the Duke University Medical Center Institutional Review Board.

**Isolation of CD133<sup>+</sup> and CD133<sup>-</sup> tumour cells.** Matched subpopulations were separated as described<sup>3,5</sup> with modifications<sup>26</sup>.

**Alkaline comet assay.** DNA damage repair was assessed by single-cell gel electrophoresis assay under alkaline conditions as described<sup>21</sup>.

**Immunofluorescent staining.** Immunofluorescent staining for neural stem cell markers (CD133, Nestin, Sox2 and Musashi) and differentiation markers (GFAP and S100 $\beta$ , astrocytes; O4 and GalC (Galactocerebroside), oligodendrocytes; Map-1 and TUJ1, neurons) was done as described<sup>27</sup>.

**Radiation treatment.** Cells or mice were irradiated at indicated doses with an X-RAD 320 irradiation system (AGFA).

***In vitro* cell mixing and repopulation.** CD133<sup>+</sup> derived from glioma xenografts or primary glioblastoma specimens were labelled with CellTracker CFSE green fluorescent dye (Molecular Probes), and the CD133<sup>-</sup> cells were labelled with the CellTracker Red CMTPX (Molecular Probes) separately according to the instructions, and then mixed in defined ratios. Triplicate parallel cultures were left untreated or treated with IR (5 Gy). The resulting growth patterns of each tumour cell population at indicated time point was visualized by fluorescent microscopy and analysed by FACS.

**Western analysis.** Immunoblotting was done as described<sup>18,19</sup>.

**Intracranial tumour assays.** Intracranial transplantation of CD133<sup>+</sup> or CD133<sup>-</sup> cells into brains of nude mice was done as described<sup>13,26</sup>.

**Statistical analysis.** The level of significance was determined by a two-tailed Student's *t*-test or analysis of variance with  $\alpha = 0.05$  (GraphPad software). All quantitative data presented are the mean  $\pm$  s.d. from at least three samples per data point.

Received 1 June; accepted 7 September 2006.

Published online 18 October 2006.

- Legler, J. M. *et al.* Brain and other central nervous system cancers: recent trends in incidence and mortality. *J. Natl Cancer Inst.* **91**, 1382–1390 (1999).
- Garden, A. S. *et al.* Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. *Radiother. Oncol.* **20**, 99–110 (1991).
- Singh, S. K. *et al.* Identification of human brain tumour initiating cells. *Nature* **432**, 396–401 (2004).
- Hemmati, H. D. *et al.* Cancerous stem cells can arise from pediatric brain tumours. *Proc. Natl Acad. Sci. USA* **100**, 15178–15183 (2003).
- Singh, S. K. *et al.* Identification of a cancer stem cell in human brain tumours. *Cancer Res.* **63**, 5821–5828 (2003).
- Uchida, N. *et al.* Direct isolation of human central nervous system stem cells. *Proc. Natl Acad. Sci. USA* **97**, 14720–14725 (2000).
- Galli, R. *et al.* Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res.* **64**, 7011–7021 (2004).
- Izant, J. G., Weatherbee, J. A. & McIntosh, J. R. A microtubule-associated protein antigen unique to mitotic spindle microtubules in PtK1 cells. *J. Cell Biol.* **96**, 424–434 (1983).
- Ignatova, T. N. *et al.* Human cortical glial tumours contain neural stem-like cells expressing astroglial and neuronal markers *in vitro*. *Glia* **39**, 193–206 (2002).
- Sanai, N. *et al.* Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. *Nature* **427**, 740–744 (2004).
- Reynolds, B. A. & Weiss, S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* **255**, 1707–1710 (1992).
- Oostendorp, R. A., Audet, J., Miller, C. & Eaves, C. J. Cell division tracking and expansion of hematopoietic long-term repopulating cells. *Leukemia* **13**, 499–501 (1999).
- Marin, L. *et al.* Flow cytometric quantification of apoptosis and proliferation in mixed lymphocyte culture. *Cytometry A* **51**, 107–118 (2003).
- Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes Dev.* **15**, 2177–2196 (2001).
- Carr, A. M. DNA structure dependent checkpoints as regulators of DNA repair. *DNA Repair* **1**, 983–994 (2002).
- Zhou, B. B. & Elledge, S. J. The DNA damage response: putting checkpoints in perspective. *Nature* **408**, 433–439 (2000).
- Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. *Nature* **432**, 316–323 (2004).
- Ali, A. *et al.* Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation. *Genes Dev.* **18**, 249–254 (2004).
- Bao, S. *et al.* ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. *Nature* **411**, 969–974 (2001).
- Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K. & Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu. Rev. Biochem.* **73**, 39–85 (2004).
- Tice, R. R. *et al.* Single cell gel/comet assay: guidelines for *in vitro* and *in vivo* genetic toxicology testing. *Environ. Mol. Mutagen.* **35**, 206–221 (2000).
- Balajee, A. S. & Geard, C. R. Replication protein A and  $\gamma$ -H2AX foci assembly is triggered by cellular response to DNA double-strand breaks. *Exp. Cell Res.* **300**, 320–334 (2004).

23. Curman, D. *et al.* Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. *J. Biol. Chem.* **276**, 17914–17919 (2001).
24. Gorgoulis, V. G. *et al.* Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**, 907–913 (2005).
25. Bartkova, J. *et al.* DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**, 864–870 (2005).
26. Bao, S. *et al.* Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. *Cancer Res.* **66**, 7843–7848 (2006).
27. Lee, A. *et al.* Isolation of neural stem cells from the postnatal cerebellum. *Nature Neurosci.* **8**, 723–729 (2005).

**Supplementary Information** is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Acknowledgements** We thank Y. H. Sun, S. Keir, D. Satterfield, L. Ehinger and J. Faison for technical assistance; M. Cook and T. R. Dissanayake for assistance with flow cytometry; Z. Lu for assistance with fluorescent microscopy; and X.-F. Wang, H. Lin, T.P. Yao, H. Friedman and R. Wechsler-Reya for discussions.

Financial support was provided by the Childhood Brain Tumor Foundation, the Pediatric Brain Tumor Foundation of the United States, Accelerate Brain Cancer Cure, a grant from the Duke Comprehensive Cancer Center Kislak–Fields Family Fund (to J.N.R.), and grants from the NIH (to J.N.R. and to D.D.B.). J.N.R. is a Damon Runyon–Lilly Clinical Investigator supported by the Damon Runyon Cancer Research Foundation and a Sidney Kimmel Foundation for Cancer Research Scholar. A.B.H. is a Paul Brazen/American Brain Tumor Association Fellow.

**Author Contributions** Q.W., S.B., Y.H. and Q.S. did the experimental work. R.E.M. performed pathological analysis and assisted in human tumour specimen acquisition. S.B. and J.N.R. wrote the paper and designed the experiments. A.B.H., M.W.D. and D.D.B. provided intellectual input and helped with experimental design.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to J.N.R. ([rich0001@mc.duke.edu](mailto:rich0001@mc.duke.edu)).